New V.P. of Clinical and Market Development
Cerapedics Appoints Patrick O’Connor as Vice President of Clinical and Market Development
Find out moreCerapedics announces ISASS bone grafting policy statement
Society states company's drug-device combination technology shown to be safe and effective as autograft replacement with compelling clinical evidence .
Find out moreCerapedics named company of the year
MedTech Outlook’s Top 10 Orthopedic Solution Providers.
Find out moreCerapedics named as a finalist for company of the year
The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.
Find out moreCerapedics announces first patients enrolled in IDE Clinical Trial of P-15L Bone Graft for transforaminal lumbar interbody fusion surgery
Proprietary synthetic small peptide technology (P-15) is being evaluated in patients across the U.S. with degenerative disk disease
Find out moreCerapedics announces closing of $22 million financing
Funding will accelerate commercialization and U.S. lumbar trial for i-FACTOR™ Peptide Enhanced Bone Graft
Find out moreCerapedics receives 2018 MedTech Breakthrough Award
Best New Surgical Technology Solution
Find out moreCerapedics announces results from IVANOS study of i-FACTOR Peptide Enhanced Bone Graft
Single-center randomized trial is measuring the efficacy of i-FACTOR in lumbar posterolateral spine surgery
Find out moreCerapedics announces i-FACTOR Peptide Enhanced Bone Graft adopted by more than 150 leading U.S. Hospitals
Rapid market adoption highlights advantages of synthetic small peptide technology, one of only two PMA approved bone graft supported by Level 1 human clinical data
Find out moreCerapedics announces appointment of Doug Kohrs to board of directors and names Antony Koblish Board Chair
Company announces exhibit at North American Spine Society 2017 annual meeting
Find out more
Welcome to Cerapedics
Choose your region
